Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 24 ... New research, 'ADAM-mediated amphiregulin shedding and EGFR transactivation,' is the subject of a report. According to recent research from ... mediate gene transcription and cellular proliferation in non-transformed and transformed prostate epithelial cells, as well as motility/invasiveness in transformed cells." ... to metalloprotease-or Src kinase-inhibition, in highly aggressive PC3 prostate cancer cells. These data also show that CXCL12-mediated cellular proliferation requires EGFR ...
2009 NOV 28 ... to provide proton therapy, an alternative to X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.Sam ... than I came in," said McElvany, a school superintendent from Wewoka, Okla. treated for prostatecancer. "Few people can say that during cancer treatment. The folks here made me feel ...
2009 NOV 24 ... Medivation, Inc. (NASDAQ: MDVN) announced that David Hung, M.D., president and chief executive officer, will present at Lazard Capital Markets Sixth Annual Healthcare ... for dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostatecancer. A live audio webcast of the presentation will be available on the ...
2009 NOV 26 ... is a polyphenol that is found in grapes, red wine, Rheum undulatum, and the seeds of Euphorbia lagascae. It has been previously reported that piceatannol ... we assessed the effects of piceatannol on the growth of androgen-insensitive DU145 prostatecancer cells at concentrations of 1-10 mu mol/L. Piceatannol reduced the viable numbers ...
2009 NOV 23 ... radiotherapy." "Three years later, he had a biochemical recurrence and commenced continuous luteinizing hormone-releasing hormone analog and antiandrogen ... According to a study from Hamilton, Canada, "A 49-year-old patient with high-risk prostatecancer presented to a specialist. He was treated with neoadjuvant hormonal therapy for 6 ...
2009 NOV 23 ... According to a study from the United States, "Despite clear epidemiological and genetic evidence for X-linked prostatecancer risk, all prostatecancer genes identified ...
2009 NOV 23 ... "Epidemiological and molecular evidence suggest potential associations between exercise and prostate cancer risk reduction. We further characterized this relationship by examining exercise and ...
2009 NOV 23 ... "We examined natural history, predictors of biochemical recurrence and all cause mortality in patients with persistently elevated prostate specific antigen ... specific antigen after radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. We reviewed data on 1,156 men treated with radical prostatectomy after ...
2009 NOV 23 ... Scientists discuss in 'Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells' new findings ... Systemic delivery of EGF-SubA results in a significant inhibition of human breast and prostate tumor xenografts in mouse models," wrote J.M. Backer and colleagues, SibTech, Inc. ...
2009 NOV 23 ... or external beam radiation therapy. At each visit urologists assessed fatigue, pain, and sexual, urinary and bowel dysfunction. independently completed the SF-36 ™ and the ... According to a study from the United States, "As the number of prostatecancer survivors increases, urologists must recognize their quality of life impairment. ...
2009 NOV 23 ... publish new data in the report 'The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.' "CC chemokine ligand 2 ... States report. "TAMs have been shown to promote tumor growth in several cancer types. Osteoclasts have also been known to play an important role in cancer bone ...
2009 NOV 23 ... Clinic research studied the association between prostate-specific antigen (PSA) levels andprostate size and found that routine annual evaluation of prostate growth is not ... of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate ...
2009 NOV 23 ... in complications such as sexual dysfunction, poor quality of life, vasomotor symptoms and altered cognition. Since estrogen is associated with cardiovascular risks, ... the United States, "The profound hypogonadism due to androgen deprivation therapy for prostatecancer results in complications such as sexual dysfunction, poor quality of life, ...
2009 NOV 23 ... our knowledge, do not exist." "We obtained data on age-specific incidence and initial course of therapy from the National Cancer Institute's Surveillance, ... research from the United States, "Although there is uncertainty about the effect of prostate-specific antigen (PSA) screening on the rate of prostate cancer death, there is little ...
2009 NOV 23 ... Investigators publish new data in the report 'Prostatecancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.' According to recent ...
2009 NOV 25 ... According to recent research published in the journal IEEE Transactions on Dielectrics and Electrical Insulation, "The effects of nanosecond pulsed electric fields (nsPEF) on the ... Insulation, "The effects of nanosecond pulsed electric fields (nsPEF) on the human prostatecancer cell line LNCaP was investigated for changes in protein and DNA concentrations as ...
2009 NOV 23 ... Investigators publish new data in the report 'Breast, colorectal and prostate cancer screening for cancer survivors and non-cancer patients in community practices.' ...
2009 NOV 23 ... are strongly associated with prostatecancer risk. The effect of these risk variants and their cumulative effect in other populations are unknown," investigators in the United ...
2009 NOV 23 ... congress worldwide on the topic of particle or ion therapy - radiation with heavy ions and protons - has taken place in the fall of 2009 in Heidelberg. Well over 600 international ... chordomas, chondrosarcomas and meningiomas as well as tumors of the salivary glands and prostate carcinomas. Brain tumors such as glioblastomas and low-grade astrocytomas will also be ... for Heavy Ion Research in Darmstadt and the Department of Medical Physics at the German Cancer Research Center (DKFZ) in Heidelberg, as well as the Rossendorf Research Center in ...
2009 NOV 23 ... eventually advance to CRPC. Prostatecancer is the most frequently diagnosed cancerand the second leading cause of cancer related deaths among men in the U.S. ...
